We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc.  (“Checkmate” or the “Company”) (NASDAQ: CMPI), in connection with the proposed acquisition of the Company by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), via a tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $10.50 in cash for each share of Checkmate common stock owned.  The transaction is valued at $250 million.

Weiss Law is investigating whether (i) Checkmate’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $10.50 per-share merger consideration adequately compensates Checkmate’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.